Patents by Inventor Esther C. W. BREIJ

Esther C. W. BREIJ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES
    Publication number: 20240252635
    Abstract: The disclosure relates to pharmaceutical compositions comprising CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The disclosure also relates to use of these pharmaceutical compositions for the treatment of cancer and other diseases.
    Type: Application
    Filed: October 4, 2019
    Publication date: August 1, 2024
    Inventors: Simone OOSTINDIE, Frank BEURSKENS, Esther C. W. BREIJ, Edward N. VAN DEN BRINK, Andreas HOLLENSTEIN, Marije OVERDIJK, Margaret LINDORFER, Ronald TAYLOR, Paul PARREN, Hilma VAN DER HORST, Martine E. D. CHAMULEAU, Tuna MUTIS, Christian CIMANDER, Martin SAHLIN, Shan REN, Abbas RAZVI, Christoph GRAPENTIN
  • ANTIBODIES BINDING TO CD30 AND CD3
    Publication number: 20240228641
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Application
    Filed: September 29, 2023
    Publication date: July 11, 2024
    Inventors: David SATIJN, Patrick ENGELBERTS, Kristel KEMPER, Esther C. W. BREIJ, Simone OOSTINDIE, Farshid ALEMDEHY
  • Antibodies
    Patent number: 11970544
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 30, 2024
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES BINDING TO CD30 AND CD3
    Publication number: 20240132607
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 25, 2024
    Inventors: David SATIJN, Patrick ENGELBERTS, Kristel KEMPER, Esther C. W. BREIJ, Simone OOSTINDIE, Farshid ALEMDEHY
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240034812
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: September 10, 2021
    Publication date: February 1, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
    Patent number: 11858995
    Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 2, 2024
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Jenny Jianlin Chen, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
    Patent number: 11845805
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 19, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Antibodies binding to CD30 and CD3
    Patent number: 11814437
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: November 14, 2023
    Assignee: GENMAB A/S
    Inventors: David Satijn, Patrick Engelberts, Kristel Kemper, Esther C. W. Breij, Simone Oostindie, Farshid Alemdehy
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230357440
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230312758
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, cHRISTOPHER W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER
    Publication number: 20230257479
    Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Type: Application
    Filed: September 11, 2020
    Publication date: August 17, 2023
    Inventors: David SATIJN, Esther C.W. BREIJ, Bart E.C.G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN, Reshma Abdulla RANGWALA, Sri GHATTA, Ruud BRAKENHOFF, Rieneke VAN DE VEN
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODIES BINDING TO CD30 AND CD3
    Publication number: 20230132049
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Application
    Filed: October 6, 2022
    Publication date: April 27, 2023
    Inventors: David SATIJN, Patrick Engelberts, Kristel Kemper, Esther C.W. Breij, Simone OOSTINDIE, Farshid ALEMDEHY
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11608383
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: March 21, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20230027495
    Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: January 26, 2023
    Applicants: Genmab A/S, MSD International GmbH
    Inventors: Reshma Abdulla RANGWALA, Esther C.W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Anthony CAO, Shyra GARDAI
  • Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
    Patent number: 11535679
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 27, 2022
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W. Breij
  • METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
    Publication number: 20220387485
    Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 8, 2022
    Applicant: Genmab A/S
    Inventors: Reshma A RANGWALA, Esther C,W. BREIJ, Sandra VERPLOEGEN, Oyewale O. ABIDOYE, Leonardo V. NICACIO
  • ANTIBODIES
    Publication number: 20220324980
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 15, 2022
    Publication date: October 13, 2022
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W BREIJ
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20220144964
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
    Type: Application
    Filed: December 22, 2021
    Publication date: May 12, 2022
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W. L. CHIU, Esther C. W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL